The global MRI-Safe CRT devices market is witnessing significant momentum, poised to more than double in size over the next decade. Valued at USD 550.5 million in 2022, the market is projected to ...

EBR Systems announced that it received commitments for a fully underwritten institutional placement to raise $36.1 million ...

Major adverse events remained common in patients with nonischemic cardiomyopathy implanted with an electronic device. Women and those who received cardiac resynchronization therapy had better ...

The heart is arguably one of the most critical organs within the human body, pumping oxygen-rich blood throughout. While ...

Recent FDA updates in the areas of cardiac intervention, hypertension and arrhythmia disorders expand the pool of available ...

EBR’s WISE CRT System is the world’s only wireless ... endocardial stimulation for bradycardia and other non-cardiac indications. The device is an investigational device in most markets ...

Background: Many patients eligible for cardiac resynchronization therapy (CRT ... patients undergoing the new implantation of a CRT device between April 15, 2004 and August 6, 2007.

cardiac resynchronization therapy, or antitachycardia pacing) are important drawbacks. In summary, many advances have been made in drug, ablation, and device therapy for cardiac arrhythmias (Fig.

CRT has been shown to improve functional status and quality of life in a significant number of these individuals. The effect of CRT on mortality and hospitalizations will emerge with final ...